您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > AVE-1625
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
AVE-1625
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
AVE-1625图片
CAS NO:358970-97-5
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议

产品介绍
AVE-1625 (AVE1625) 是一种具有口服活性的 CB1 受体拮抗剂。
Cas No.358970-97-5
别名屈那班,Drinabant
化学名N-[1-[bis(4-chlorophenyl)methyl]azetidin-3-yl]-N-(3,5-difluorophenyl)methanesulfonamide
Canonical SMILESCS(=O)(N(C1CN(C(C2=CC=C(Cl)C=C2)C3=CC=C(Cl)C=C3)C1)C4=CC(F)=CC(F)=C4)=O
分子式C23H20Cl2F2N2O2S
分子量497.4
溶解度≤0.15mg/ml in ethanol;15mg/ml in DMSO;15mg/ml in dimethyl formamide
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

AVE-1625 is a highly potent, selective antagonist for the CB1 receptor [1].

The cannabinoid receptor type 1 (CB1) is a G protein-coupled receptor mainly expressed in the central and peripheral nervous system. The CB1 receptor is activated by the endocannabinoid neurotransmitters anandamide and 2-arachidonoylglycerol (2-AG). The CB1 receptor has been implicated in the maintenance of homeostasis in health and disease [2]. The CB1 receptor plays vital roles in modulating neurotransmitter release by preventing the development of excessive neuronal activity, reducing pain and other inflammatory symptoms [2].

AVE-1625 antagonized the CB1 receptor activity with the Ki values of 0.16-0.44 nM [1]. Treatment with AVE-1625 (1-3 mg/kg) significantly improved the performance of rodents in working memory tasks. At 30 mg/kg, AVE-1625 reduced caloric intake by more than 50% of controls and significantly increased lipolysis from fat tissues and reduced hepatic glycogen levels in rodents. In Wistar rats, postprandially administration of AVE1625 slightly increased the basal lipolysis in a dose-dependent manner. AVE1625 caused primary effects on metabolic blood and tissue parameters as well as metabolic rate [3]. As measured by indirect calorimetry, AVE1625 immediately increased the total energy expenditure and a transiently increased glucose oxidation [3].

References:
[1] Borowsky B, Stevens R, Mark B, et al.  AVE1625, a cannabinoid CBI antagonist, as a co-treatment for schizophrenia: Improvement in cognitive function and reduction of antipsychotic-side effects in animal models[C]//Neuropsychopharmacology. Macmillan building, 4 crinan st, london n1 9xw, ENGLAND: NATURE PUBLISHING GROUP, 2005, 30: S116-S117.
[2] Herkenham M, Lynn A B, Little M D, et al.  Cannabinoid receptor localization in brain[J]. Proceedings of the national Academy of sciences, 1990, 87(5): 1932-1936.
[3] Herling A W, Gossel M, Haschke G, et al.  CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats[J]. American Journal of Physiology-Endocrinology and Metabolism, 2007, 293(3): E826-E832.